Hypermarcas (OTCMKTS:HYPMY) Announces Earnings Results

Key Points

• Hypermarcas reported quarterly earnings of $0.12 per share, with a return on equity of 6.19% and a net margin of 11.28%.
• The company announced a dividend of $0.0345, yielding 281.0%, to be paid on January 8th.
• Scotiabank has upgraded Hypermarcas to a "strong-buy" rating, indicating positive analyst sentiment towards the stock.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, Zacks reports. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas Price Performance

HYPMY stock traded up $0.22 during mid-day trading on Friday, reaching $4.44. The company's stock had a trading volume of 10,504 shares, compared to its average volume of 66,615. Hypermarcas has a fifty-two week low of $2.64 and a fifty-two week high of $5.92. The stock has a market cap of $2.81 billion, a PE ratio of 21.14 and a beta of 0.77. The company's 50 day moving average is $4.76 and its two-hundred day moving average is $3.97. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.63.

Hypermarcas Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, July 1st will be issued a $0.0345 dividend. This represents a yield of 281.0%. The ex-dividend date is Monday, June 30th. Hypermarcas's payout ratio is presently 50.00%.

Analysts Set New Price Targets

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.